Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papi (Ferrera, Italy), L. Lee (Collegeville, PA, United States of America), H. Kerstjens (Groningen, Netherlands), L. Boulet (Quebec, QC, Canada), A. Zarankaite (Stockley Park West, Uxbridge, Middlesex, United Kingdom), I. Pavord (Oxford, United Kingdom), G. Brusselle (Ghent, Belgium), N. Barnes (Brentford, Middlesex and London, United Kingdom), N. Hanania (Houston, TX, United States of America), S. Pascoe (Collegeville, PA, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Pizzichini (Brentford, Middlesex (UK) and Santa Catarina, Brazil), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom). CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA. 2272

Member's Comments

No comment yet.

Related content which might interest you: CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy Source: Eur Respir J 2005; 26: Suppl. 49, 382s Year: 2005 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Changes in the use of anti-asthmatic medication in an international cohort Source: Eur Respir J 2005; 26: 1047-1055 Year: 2005 Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking Source: Eur Respir J 2006; 28: Suppl. 50, 454s Year: 2006 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial Source: International Congress 2018 – Educational tools to improve your practice Year: 2018